Exploratory analysis from Phase 1b/2 breast cancer trial reinforces CD47 as a predictive biomarker for response, as ...

New data from a phase 1b/2 clinical trial shows that a specific protein called CD47 can help predict how well the investigational drug evorpacept works for patients with metastatic breast cancer, ALX ...

Discover the key differences between Data Science, Data Engineering, and AI. Learn about their unique roles, technical ...

Supervised learning algorithms like Random Forests, XGBoost, and LSTMs dominate crypto trading by predicting price directions ...

Exploratory analysis from Phase 1b/2 breast cancer trial reinforces CD47 as a predictive biomarker for response, as previously observed in the ASPEN-06 trial in HER2-positive gastric cancer – ...

People familiar with the rollout say Kepler is not a consumer product and is restricted to internal use, aimed at reducing ...

Generative AI (GenAI) has moved rapidly from experimentation into day-to-day use across many organizations. Over the past ...

EGFR drug ALX2004 and evorpacept, which recently showed activity with Jazz's Ziihera in CD47- and HER2-positive breast cancer.

Viking Therapeutics has provided a series of updates this January concerning its clinical development pipeline, with a primary focus on its obesity treatment ca ...

Anxiety and depression significantly affect health-related QOL among individuals with DGBI, such as IBS and dyspepsia.

The Phase Ib/II trial assessed evorpacept plus zanidatamab in previously treated, metastatic HER2-expressing cancers.

CD47 expression levels may predict evorpacept efficacy in HER2-positive metastatic breast cancer, especially in heavily pretreated patients. Evorpacept combined with zanidatamab shows promising ...